BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 17511564)

  • 21. Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy.
    Guo C; Willem M; Werner A; Raivich G; Emerson M; Neyses L; Mayer U
    Hum Mol Genet; 2006 Mar; 15(6):989-98. PubMed ID: 16476707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiomyopathy in the dystrophin/utrophin-deficient mouse model of severe muscular dystrophy is characterized by dysregulation of matrix metalloproteinases.
    Delfín DA; Zang KE; Schill KE; Patel NT; Janssen PM; Raman SV; Rafael-Fortney JA
    Neuromuscul Disord; 2012 Nov; 22(11):1006-14. PubMed ID: 22749475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers.
    Miyazaki D; Nakamura A; Fukushima K; Yoshida K; Takeda S; Ikeda S
    Hum Mol Genet; 2011 May; 20(9):1787-99. PubMed ID: 21320869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of brain utrophin does not rescue behavioral alterations in dystrophin-deficient mice.
    Perronnet C; Chagneau C; Le Blanc P; Samson-Desvignes N; Mornet D; Laroche S; De La Porte S; Vaillend C
    Hum Mol Genet; 2012 May; 21(10):2263-76. PubMed ID: 22343141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dystrophin delivery in dystrophin-deficient DMDmdx skeletal muscle by isogenic muscle-derived stem cell transplantation.
    Ikezawa M; Cao B; Qu Z; Peng H; Xiao X; Pruchnic R; Kimura S; Miike T; Huard J
    Hum Gene Ther; 2003 Nov; 14(16):1535-46. PubMed ID: 14577915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac dysfunction and pathology in the dystrophin and utrophin-deficient mouse during development of dilated cardiomyopathy.
    Chun JL; O'Brien R; Berry SE
    Neuromuscul Disord; 2012 Apr; 22(4):368-79. PubMed ID: 22266080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies.
    Banks GB; Chamberlain JS
    Curr Top Dev Biol; 2008; 84():431-53. PubMed ID: 19186250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy.
    Gardner KL; Kearney JA; Edwards JD; Rafael-Fortney JA
    Gene Ther; 2006 May; 13(9):744-51. PubMed ID: 16307000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study on the gene knockout model mice of Duchenne muscular dystrophy].
    Chen S; Zhang C; Liu X; Gao L; Zhang W; Huang W; Lu X; Wang Z
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Apr; 34(2):210-3. PubMed ID: 12947691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utrophin Compensates dystrophin Loss during Mouse Spermatogenesis.
    Chen HC; Chin YF; Lundy DJ; Liang CT; Chi YH; Kuo P; Hsieh PCH
    Sci Rep; 2017 Aug; 7(1):7372. PubMed ID: 28785010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy.
    D'Arcy CE; Feeney SJ; McLean CA; Gehrig SM; Lynch GS; Smith JE; Cowling BS; Mitchell CA; McGrath MJ
    Hum Mol Genet; 2014 Feb; 23(3):618-36. PubMed ID: 24087791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exercise increases utrophin protein expression in the mdx mouse model of Duchenne muscular dystrophy.
    Gordon BS; Lowe DA; Kostek MC
    Muscle Nerve; 2014 Jun; 49(6):915-8. PubMed ID: 24375286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Social stress is lethal in the mdx model of Duchenne muscular dystrophy.
    Razzoli M; Lindsay A; Law ML; Chamberlain CM; Southern WM; Berg M; Osborn J; Engeland WC; Metzger JM; Ervasti JM; Bartolomucci A
    EBioMedicine; 2020 May; 55():102700. PubMed ID: 32192914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Utrophin, a way to cure Duchenne muscle dystrophy].
    Gillis JM
    Med Sci (Paris); 2004 Apr; 20(4):442-7. PubMed ID: 15124117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.
    Morales MG; Gutierrez J; Cabello-Verrugio C; Cabrera D; Lipson KE; Goldschmeding R; Brandan E
    Hum Mol Genet; 2013 Dec; 22(24):4938-51. PubMed ID: 23904456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of utrophin at dystrophin-deficient neuromuscular synapses of mdx mice: a study of protected and affected muscles.
    Ferretti R; Neto HS; Marques MJ
    Anat Rec (Hoboken); 2011 Feb; 294(2):283-6. PubMed ID: 21235003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice.
    Ito K; Kimura S; Ozasa S; Matsukura M; Ikezawa M; Yoshioka K; Ueno H; Suzuki M; Araki K; Yamamura K; Miwa T; Dickson G; Thomas GD; Miike T
    Hum Mol Genet; 2006 Jul; 15(14):2266-75. PubMed ID: 16777842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy.
    Bia BL; Cassidy PJ; Young ME; Rafael JA; Leighton B; Davies KE; Radda GK; Clarke K
    J Mol Cell Cardiol; 1999 Oct; 31(10):1857-62. PubMed ID: 10525423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TAT-μUtrophin mitigates the pathophysiology of dystrophin and utrophin double-knockout mice.
    Call JA; Ervasti JM; Lowe DA
    J Appl Physiol (1985); 2011 Jul; 111(1):200-5. PubMed ID: 21565990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Future treatment modalities in Duchenne muscular dystrophy].
    Oron A; Shuper A; Shohat M
    Harefuah; 1998 Apr; 134(7):557-60. PubMed ID: 10909603
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.